NetworkNewsBreaks – Kaival Brands Innovations Group Inc. (KAVL) Acquires US Patent and International Patent Applications, Forms Kaival Labs Inc.
Kaival Brands (OTCQB: KAVL), a company focused on growing and incubating innovative and profitable products into mature, dominant brands, on Monday announced its entry into a Patent Contribution Agreement (the “Agreement”), under which it will acquire exclusive rights to an international patent portfolio concerning full customization of certain isomeric properties of synthetic nicotine. In addition, the company announced the formation of a new wholly owned subsidiary, Kaival Labs Inc., a Delaware corporation that will own and develop the patent. “The science behind these patents has discovered that within the nicotine molecule the S-isomers control the addictive properties, whereas the R-isomers control the beneficial qualities of the nicotine that a user enjoys,” said Kaival Brands CEO Niraj Patel in the news release. “The exclusivity is that the patents allow us to control the specific ratios of each isomer in the final synthetic nicotine molecule we produce for cessation products. We can now create completely unique products for smoking cessation and nicotine addiction therapy that remain effective and satisfying for the user but are free from nicotine’s addictive traits.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Kaival Brands (OTCQB: KAVL), a company focused on growing and incubating innovative and profitable products into mature, dominant brands, on Monday announced its entry into a Patent Contribution Agreement (the “Agreement”), under which it will acquire exclusive rights to an international patent portfolio concerning full customization of certain isomeric properties of synthetic nicotine. In addition, the company announced the formation of a new wholly owned subsidiary, Kaival Labs Inc., a Delaware corporation that will own and develop the patent. “The science behind these patents has discovered that within the nicotine molecule the S-isomers control the addictive properties, whereas the R-isomers control the beneficial qualities of the nicotine that a user enjoys,” said Kaival Brands CEO Niraj Patel in the news release. “The exclusivity is that the patents allow us to control the specific ratios of each isomer in the final synthetic nicotine molecule we produce for cessation products. We can now create completely unique products for smoking cessation and nicotine addiction therapy that remain effective and satisfying for the user but are free from nicotine’s addictive traits.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
